Belite Bio在2025年11月10日创下52周高位, Belite Bio hit a 52-week high on Nov. 10, 2025, despite a quarterly loss and mixed analyst views.

贝莱特生物 (BLTE) 在2025年11月10日创下52周高点117.89美元,在分析师情绪不一的情况下收盘在111.9990美元,每股季度亏损0.65美元,不符合预期. Belite Bio (BLTE) hit a 52-week high of $117.89 on November 10, 2025, closing at $111.9990 amid mixed analyst sentiment and a quarterly loss of $0.65 per share, missing expectations. 该公司为视网膜疾病开发了LBS-008(Tinlarebant),市场上限为36.2亿美元,协商一致的“Moderate Buy”评级为“Moderate Buy”,平均价格目标为113.33美元。 The company, developing LBS-008 (Tinlarebant) for retinal diseases, has a market cap of $3.62 billion and a consensus "Moderate Buy" rating with a $113.33 average price target. 尽管损失比预期的要大,而且-73.41的P/E值为负值,但股票的贸易量强劲上升。 Despite a wider-than-expected loss and negative P/E of -73.41, the stock rose on strong trading volume. 分析家预测,每股全年损失1.17美元,股票的贝塔为-1.42,表明市场波动反向。 Analysts project a full-year loss of $1.17 per share, and the stock’s beta of -1.42 indicates inverse market volatility.